An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
Top results in this bookTable of Contents
Systematic review of treatments for atopic eczema.
Hoare C, Li Wan Po A, Williams H.
Southampton (UK): NIHR Journals Library; 2000 Dec. (Health Technology Assessment, No. 04.37.)
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
NTP Technical Report on the Toxicity Studies of Octahydro-tetramethyl-naphthalenyl-ethanone (OTNE) Administered Dermally to F344/NTac Rats and B6C3F1/N Mice: Toxicity Report 92 [Internet].
National Toxicology Program.
Research Triangle Park (NC): National Toxicology Program; 2016 Jun.
Clinical Review Report: Dupilumab (Dupixent): (Sanofi Genzyme, a division of sanofi-aventis Canada Inc.): Indication: Indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jun.
Itch: Mechanisms and Treatment.
Carstens E, Akiyama T, editors.
Boca Raton (FL): CRC Press/Taylor & Francis; 2014.
Scoping systematic review of treatments for eczema.
Nankervis H, Thomas KS, Delamere FM, et al.
Southampton (UK): NIHR Journals Library; 2016 May. (Programme Grants for Applied Research, No. 4.7.)
Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr.
Upadacitinib (Rinvoq): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
A behaviour change package to prevent hand dermatitis in nurses working in health care: the SCIN cluster RCT.
Madan I, Parsons V, Ntani G, et al.
Southampton (UK): NIHR Journals Library; 2019 Oct. (Health Technology Assessment, No. 23.58.)
Clinical Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-severe atopic dermatitis (AD) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jul.
GeneReviews® [Internet].
Adam MP, Bick S, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2026.
Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness.
Pickett K, Loveman E, Kalita N, et al.
Southampton (UK): NIHR Journals Library; 2015 Oct. (Health Technology Assessment, No. 19.86.)
Abrocitinib (Cibinqo): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis, moderate to severe [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
Tralokinumab (Adtralza): Therapeutic area: Atopic dermatitis: CADTH Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Sep.
InformedHealth.org [Internet].
Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-.
Tralokinumab (Adtralza): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun.
Ruxolitinib (Opzelura): Therapeutic area: Atopic dermatitis: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Sep.
Pharmacoeconomic Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older [Internet].
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on